Web Analytics Made Easy - StatCounter
Category

Breast Cancer

Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells.

By | Breast Cancer, Cancer

Authors: Sean D. McAllister, Rigel T. Christian, Maxx P. Horowitz, Amaia Garcia, Pierre-Yves Desprez
Molecular Cancer Therapeutics, November 2007

Invasion and metastasis of aggressive breast cancer cells is the final and fatal step during cancer progression, and is the least understood genetically. Clinically, there are still limited therapeutic interventions for aggressive and metastatic breast cancers available. Clear…

Read More

The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism.

By | Breast Cancer, Cancer

Authors: Daniela Sarnataro, Simona Pisanti, Antonietta Santoro, Patrizia Gazzerro, et al
Molecular Pharmacology, October 2006

The endocannabinoid system has been shown to modulate key cell-signaling pathways involved in cancer cell growth. In this study, we show that cannabinoid receptor type 1 (CB1) antagonist Rimonabant (SR141716) inhibited human breast cancer cell proliferation, being more effecti…

Read More

Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.

By | Breast Cancer, Cancer

Authors: Alessia Ligresti, Aniello Schiano Moriello, Katarzyna Starowicz, Isabel Matias, et al
Journal of Pharmacology and Experimental Therapeutics, September 2006

Delta(9)-Tetrahydrocannabinol (THC) exhibits antitumor effects on various cancer cell types, but its use in chemotherapy is limited by its psychotropic activity. We investigated the antitumor activities of other plant cannabinoids, i.e., cannabidiol, cannabigerol, cannabichrom…

Read More

Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.

By | Breast Cancer, Cancer

Authors: María M. Caffarel, David Sarrió, José Palacios, Manuel Guzmán, Cristina Sánchez
Cancer Research, 1 July 2006

It has been proposed that cannabinoids are involved in the control of cell fate. Thus, these compounds can modulate proliferation, differentiation, and survival in different manners depending on the cell type and its physiopathologic context. However, little is known about the…

Read More

Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.

By | Breast Cancer, Cancer, Prostatic Cancer

Authors: Dominique Melck, Luciano De Petrocellis, Pierangelo Orlando, Tiziana Bisogno, et al
Endocrinology, January 2000

Anandamide and 2-arachidonoylglycerol (2-AG), two endogenous ligands of the CB1 and CB2 cannabinoid receptor subtypes, inhibit the proliferation of PRL-responsive human breast cancer cells (HBCCs) through down-regulation of the long form of the PRL receptor (PRLr). Here we rep…

Read More

The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.

By | Breast Cancer, Cancer

Authors: Luciano De Petrocellis, Dominique Melck, Antonella Palmisano, Tiziana Bisogno, et al
PNAS, 7 July 1998

Anandamide was the first brain metabolite shown to act as a ligand of “central” CB1 cannabinoid receptors. Here we report that the endogenous cannabinoid potently and selectively inhibits the proliferation of human breast cancer cells in vitro. Anandamide dose-dependently inhi…

Read More